指南与共识骨质疏松与代谢性骨病骨肿瘤

国际骨质疏松基金会关于意义未明单克隆丙种球蛋白病(MGUS)患者骨脆性评估与管理的临床指导意见

Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement.
指南 / 共识 · Osteoporos Int · 2026-09-08

MGUS 是老年常见的血液学异常,与脆性骨折风险升高相关。该 IOF 立场声明汇总骨折流行病学、骨密度、骨微结构、骨转换标志物及骨组织形态计量学证据,提出风险适应治疗策略并建议双膦酸盐为 preferred 治疗选择。

要点

  • MGUS 患者骨折风险升高,尤其合并骨质疏松危险因素或共病时。
  • MGUS 与骨密度降低相关,机制涉及骨吸收增加。
  • 针对 MGUS 骨损害的治疗研究有限,推荐风险适应治疗策略。

核心结论

  • MGUS 与脆性骨折风险升高相关,建议对 MGUS 患者进行骨评估并采用风险适应治疗策略。

研究设计与样本

  • 国际骨质疏松基金会(IOF)立场声明,基于综述汇总 MGUS 患者骨折流行病学、骨密度、骨微结构、骨转换标志物及骨组织形态计量学数据。

主要发现

  • MGUS 患者骨折风险升高,尤其在存在骨质疏松危险因素或共病时。
  • MGUS 患者骨密度降低,与骨吸收增加相关。
  • 针对 MGUS 骨损害的治疗研究有限。

关键数值与推荐

  • 推荐对 MGUS 患者采用风险适应治疗策略。
  • 建议双膦酸盐作为 MGUS 骨损害 preferred 治疗选择。

临床怎么用

  • 对 MGUS 患者应评估骨折风险及骨密度,结合骨质疏松危险因素与共病制定管理方案。
  • 在治疗选择上,可考虑双膦酸盐作为 preferred 选项。

局限性

  • 针对 MGUS 骨损害治疗的研究有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Monoclonal gammopathy of undetermined significance (MGUS) is a frequent hematological condition that occurs in later life. MGUS is associated with increased fragility fractures that mix individual osteoporotic risk factors, MGUS-related comorbidities, and direct MGUS bone impact such as senescence of plasma cells. This International Osteoporosis Foundation (IOF) position statement aims at evaluating the potential relationship between MGUS and fracture risk, as well as methods for evaluating bone involvement in MGUS. Finally, we propose the first bone clinical guidance for patients with MGUS to improve their bone health. BACKGROUND: Monoclonal gammopathy of undetermined significance is a prevalent hematological condition in adults, characterized by the presence of an abnormal monoclonal protein in the blood without concomitant symptoms or malignancy. MGUS is of considerable bone significance and contributes to fragility fractures in adults. METHODS: In this review, data pertaining to bone fragility were collected, including epidemiological fracture data in patients with MGUS, bone mineral density (BMD), bone microarchitecture, bone turnover marker, and bone histomorphometry data. RESULTS: Collectively, these findings suggest an elevated risk of fractures, especially in presence of osteoporotic risk factors or comorbidities, and a diminished BMD due to augmented bone resorption. Studies focusing on the treatment of this condition are limited. CONCLUSION: Based on this analysis, we present the International Osteoporosis Foundation (IOF) position statement for bone evaluation and management of these patients. We recommend a risk-adapted treatment strategy. A proposal of bone clinical guidance dedicated to patients with MGUS is presented, suggesting bisphosphonates as the preferred treatment option.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Confavreux CB, Bouvard B, Blank R, et al. Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement. Osteoporos Int. 2026. PMID: 42709184. doi:10.1007/s00198-026-08178-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。